Meeting
2023 ASCO Annual Meeting
Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy.
Authors
Jennifer F. De Los Santos
Grandview Cancer Center, Birmingham, AL
Jennifer F. De Los Santos , Adam Raben , Olga Russial , Lydia Clements , Neil Hockstein , Su Park , Lana Maria De Souza Lawrence
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6083)
DOI
10.1200/JCO.2023.41.16_suppl.6083
Abstract #
6083
Poster Bd #
75
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2023 ASCO Annual Meeting
Treatment at twilight: Is less more in the management of octogenarians with non-small cell lung cancer (NSCLC)?
First Author: Ethan Burns
Poster
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
First Author: Yu Fujiwara
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
First Author: Sun Young Jeong